Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L D Locati

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Oral Oncology|September 23, 2008
Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II studyL D Locati, P Bossi, F Perrone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 15, 2011
Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancerP Bossi, E Orlandi, C Bergamini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 26, 2011
Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation studyR Granata, R Miceli, E Orlandi, et al.
ESMO Open|August 25, 2023
Corrigendum to 'Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up': [ESMO Open 7(6):100602, December 2022]C van Herpen, V Vander Poorten, A Skalova, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 14, 2026
Particle Beam Re-irradiation in Oligo Recurrent Gynecological MalignanciesA Barcellini, A Vai, G Fontana, et al.
ESMO Open|December 25, 2022
Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-upC van Herpen, V Vander Poorten, A Skalova, et al.
European Journal of Cancer (Oxford, England : 1990)|February 17, 2019
Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinomaW van Boxtel, L D Locati, A C H van Engen-van Grunsven, et al.
European Journal of Cancer (Oxford, England : 1990)|May 8, 2018
Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancerS Cavalieri, F Perrone, R Miceli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neckP Bossi, R Miceli, L D Locati, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2016
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impactL D Locati, F Perrone, B Cortelazzi, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Oral Oncology|September 23, 2008
Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II studyL D Locati, P Bossi, F Perrone, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 15, 2011
Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancerP Bossi, E Orlandi, C Bergamini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 26, 2011
Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation studyR Granata, R Miceli, E Orlandi, et al.
ESMO Open|August 25, 2023
Corrigendum to 'Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up': [ESMO Open 7(6):100602, December 2022]C van Herpen, V Vander Poorten, A Skalova, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|March 14, 2026
Particle Beam Re-irradiation in Oligo Recurrent Gynecological MalignanciesA Barcellini, A Vai, G Fontana, et al.
ESMO Open|December 25, 2022
Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-upC van Herpen, V Vander Poorten, A Skalova, et al.
European Journal of Cancer (Oxford, England : 1990)|February 17, 2019
Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinomaW van Boxtel, L D Locati, A C H van Engen-van Grunsven, et al.
European Journal of Cancer (Oxford, England : 1990)|May 8, 2018
Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancerS Cavalieri, F Perrone, R Miceli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neckP Bossi, R Miceli, L D Locati, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2016
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impactL D Locati, F Perrone, B Cortelazzi, et al.
Pageof 4